Now who do we know that was Vice President of Regu

Now who do we know that was Vice President of Regulatory Policy at Sanofi..


$100 Billion French Pharma Giant Sanofi says they're on the "Hunt" for Rare Disease Acquisitions: Here's who they may be Eyeballing - March 5, 2016

Quote:

---

The idea dovetails with Sanofi's recent statements on how it plans to reverse its slumping growth, as recently appointed CEO Olivier Brandicourt has repeatedly said the company is interested in deals big and small to counteract creeping competition and sluggish sales for its banner products. And rare diseases could be an ideal field to boost Sanofi's margins--Orphan drugs like Genzyme's Cerezyme treat small numbers of patients but command high prices, and insurers have traditionally been willing to shell out for such therapies on the belief that they prevent costlier outcomes for sufferers of rare disease.

---

http://finance.yahoo.com/news/100-billion-fre...00104.html